[HTML][HTML] Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with …
R Dziadziuszko, B Holm, BG Skov, K Osterlind… - Annals of oncology, 2007 - Elsevier
Background: Survival benefit of non-small-cell lung cancer (NSCLC) patients treated with
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is predicted by high …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is predicted by high …
Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non–Small-Cell Lung Cancer Patients Treated With First-Line EGFR …
T Jiang, J Zhao, C Zhao, X Li, J Shen, J Zhou, S Ren… - Clinical lung cancer, 2019 - Elsevier
Background There is an urgent need to develop a convenient and less invasive technique to
monitor the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors …
monitor the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors …
[HTML][HTML] Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
AL Riediger, S Dietz, U Schirmer, M Meister… - Scientific reports, 2016 - nature.com
Long-lasting success in lung cancer therapy using tyrosine kinase inhibitors (TKIs) is rare
since the tumors develop resistance due to the occurrence of molecularly altered subclones …
since the tumors develop resistance due to the occurrence of molecularly altered subclones …
Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small …
EBF Ebert, T McCulloch, KH Hansen, H Linnet… - Lung Cancer, 2020 - Elsevier
Objectives Epidermal growth factor receptor (EGFR) mutations confer sensitivity to tyrosine
kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, a subset of …
kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, a subset of …
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; …
JE Gray, MJ Ahn, GR Oxnard, FA Shepherd… - Clinical cancer …, 2023 - AACR
Purpose: Plasma circulating tumor DNA (ctDNA) analysis is used for genotyping advanced
non–small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to …
non–small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to …
[HTML][HTML] EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer
F Baty, S Rothschild, M Früh, D Betticher, C Dröge… - PloS one, 2013 - journals.plos.org
Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for
patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine …
patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine …
Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer
N Peled, K Yoshida, MW Wynes… - … advances in medical …, 2009 - journals.sagepub.com
Epidermal growth factor receptor (EGFR) related therapies-mainly tyrosine kinase inhibitors
(TKIs) such as erlotinib and gefitinib, but also monoclonal antibodies targeting EGFR, for …
(TKIs) such as erlotinib and gefitinib, but also monoclonal antibodies targeting EGFR, for …
[HTML][HTML] Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer
B Wei, K Yang, J Zhao, Y Chang, Z Ma, B Dong… - Journal of Experimental …, 2014 - Springer
Background EGFR mutation detection has been widely applied in the prediction of TKIs
therapy in Non-Small Cell Lung Cancer (NSCLC). Metastatic tumors rather than primary …
therapy in Non-Small Cell Lung Cancer (NSCLC). Metastatic tumors rather than primary …
Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?
M Marcq, A Vallée, A Bizieux, MG Denis - Journal of Thoracic Oncology, 2014 - jto.org
Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time
Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors? - Journal of Thoracic …
Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors? - Journal of Thoracic …
[HTML][HTML] Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non …
K Guo, C Shao, L Han, H Liu, Z Ma, Y Yang… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Plasma circulating tumor DNA (ctDNA) may be a surrogate, minimally invasive
approach to tissue-based epidermal growth factor receptor (EGFR) mutation detection in …
approach to tissue-based epidermal growth factor receptor (EGFR) mutation detection in …